Literature DB >> 25809135

Hyperinsulinemia in newly diagnosed patients with multiple sclerosis.

Adela Penesova1, Miroslav Vlcek, Richard Imrich, Lucia Vernerova, Andrea Marko, Milada Meskova, Lucia Grunnerova, Peter Turcani, Daniela Jezova, Branislav Kollar.   

Abstract

There are limited data regarding glucose metabolism dysregulation in multiple sclerosis (MS). Present study investigates glucose and insulin response during oral glucose tolerance test (oGTT) in MS patients. We examined 19 MS patients and 19 age, sex and body mass index (BMI) matched healthy controls. MS patients were newly diagnosed, untreated and with low Expanded Disability Status Scale (EDSS) score (1.1 ± 0.7). Plasma glucose, lactate, insulin and GLP-1 during oGTT, and fasting adipokines, lipid and inflammatory parameters were analyzed. Insulin sensitivity indices (ISI) were calculated. MS patients had comparable fasting (5.2 ± 0.3 vs. 5.0 ± 0.4 mmol/l, p = 0.05) and post-load glucose concentrations as controls. Insulin response to oral glucose load in MS was increased (p = 0.022). Insulin sensitivity was lower in MS compared to controls [ISI(Matsuda) 6.95 ± 3.44 vs. 10.60 ± 4.81, p = 0.011 and ISI(Cederholm) 49.9 ± 15.3 vs. 61.3 ± 16.3, p = 0.032]. We did not find any difference in lactate, GLP-1, total, HDL and LDL cholesterol, triglycerides, interleukin 6, tumor necrosis factor, C-reactive protein, resistin, leptin, adiponectin levels between groups. We found decreased insulin sensitivity with postprandial hyperinsulinemia in MS patients, which seems not to be related to chronic inflammation or physical inactivity. The role of hyperinsulinemia in CNS function impairment should be further investigated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25809135     DOI: 10.1007/s11011-015-9665-1

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  38 in total

Review 1.  Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  J Neurol Sci       Date:  2006-04-24       Impact factor: 3.181

2.  Elevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: a Finnish co-twin study.

Authors:  A Hietaharju; H Kuusisto; R Nieminen; K Vuolteenaho; I Elovaara; E Moilanen
Journal:  Eur J Neurol       Date:  2009-06-15       Impact factor: 6.089

3.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt
Journal:  Diabetes Care       Date:  1998-04       Impact factor: 19.112

4.  Effects of physical activity, body mass index, waist-to-hip ratio and waist circumference on total mortality risk in the Swedish National March Cohort.

Authors:  Rino Bellocco; Chongqi Jia; Weimin Ye; Ylva Trolle Lagerros
Journal:  Eur J Epidemiol       Date:  2010-08-22       Impact factor: 8.082

5.  Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination.

Authors:  Martha Zeger; Greg Popken; Jihui Zhang; Shouhong Xuan; Q Richard Lu; Markus H Schwab; Klaus-Armin Nave; David Rowitch; A Joseph D'Ercole; Ping Ye
Journal:  Glia       Date:  2007-03       Impact factor: 7.452

6.  Both type I and II IFN induce insulin resistance by inducing different isoforms of SOCS expression in 3T3-L1 adipocytes.

Authors:  Tsutomu Wada; Masashi Hoshino; Yukari Kimura; Minoru Ojima; Tetsuro Nakano; Daisuke Koya; Hiroshi Tsuneki; Toshiyasu Sasaoka
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-03-08       Impact factor: 4.310

7.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

8.  The role of norepinephrine and insulin resistance in an early stage of hypertension.

Authors:  Adela Penesova; Zofia Radikova; Eva Cizmarova; Richard Kvetnanský; Pavel Blazicek; Miroslav Vlcek; Juraj Koska; Milan Vigas
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

9.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

10.  Prolonged plasma half-life of insulin in patients with a genetic defect of high affinity binding sites.

Authors:  M Dreyer; S Matthaei; J Kühnau; H W Rüdiger
Journal:  Horm Metab Res       Date:  1986-04       Impact factor: 2.936

View more
  16 in total

Review 1.  Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration.

Authors:  Zohara Sternberg
Journal:  Neuromolecular Med       Date:  2018-02-10       Impact factor: 3.843

2.  Cardiovascular profile improvement during Natalizumab treatment.

Authors:  Marcello Moccia; Roberto Albero; Roberta Lanzillo; Francesco Saccà; Anna De Rosa; Cinzia Valeria Russo; Antonio Carotenuto; Raffaele Palladino; Vincenzo Brescia Morra
Journal:  Metab Brain Dis       Date:  2017-12-18       Impact factor: 3.584

3.  Autonomic Nervous System Function in Newly Diagnosed Multiple Sclerosis: Association With Lipid Levels and Insulin Resistance.

Authors:  M Hardoňová; P Šiarnik; M Siváková; M Suchá; M Vlček; R Imrich; P Turčáni; A Havranová; Ž Rádiková; I Žitňanová; Z Dean; A Penesová; B Kollár
Journal:  Physiol Res       Date:  2021-10-30       Impact factor: 1.881

Review 4.  Crosstalk between neurological, cardiovascular, and lifestyle disorders: insulin and lipoproteins in the lead role.

Authors:  Richa Tyagi; Bhupesh Vaidya; Shyam Sunder Sharma
Journal:  Pharmacol Rep       Date:  2022-09-23       Impact factor: 3.919

5.  Intracranial delivery of interleukin-17A via adeno-associated virus fails to induce physical and learning disabilities and neuroinflammation in mice but improves glucose metabolism through AKT signaling pathway.

Authors:  Junling Yang; Jinghong Kou; Jeong-Eun Lim; Robert Lalonde; Ken-Ichiro Fukuchi
Journal:  Brain Behav Immun       Date:  2015-11-10       Impact factor: 7.217

6.  Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats.

Authors:  Brian DellaValle; Gitte S Brix; Birgitte Brock; Michael Gejl; Anne M Landau; Arne Møller; Jørgen Rungby; Agnete Larsen
Journal:  Front Pharmacol       Date:  2016-11-18       Impact factor: 5.810

7.  Twelve Weeks of Medium-Intensity Exercise Therapy Affects the Lipoprotein Profile of Multiple Sclerosis Patients.

Authors:  Winde Jorissen; Tim Vanmierlo; Inez Wens; Veerle Somers; Bart Van Wijmeersch; Jeroen F Bogie; Alan T Remaley; Bert O Eijnde; Jerome J A Hendriks
Journal:  Int J Mol Sci       Date:  2018-01-08       Impact factor: 5.923

8.  Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL.

Authors:  Winde Jorissen; Elien Wouters; Jeroen F Bogie; Tim Vanmierlo; Jean-Paul Noben; Denis Sviridov; Niels Hellings; Veerle Somers; Roland Valcke; Bart Vanwijmeersch; Piet Stinissen; Monique T Mulder; Alan T Remaley; Jerome J A Hendriks
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

9.  Impact of Nutritional Intake on Function in People with Mild-to-Moderate Multiple Sclerosis.

Authors:  Lacey Bromley; Peter J Horvath; Susan E Bennett; Bianca Weinstock-Guttman; Andrew D Ray
Journal:  Int J MS Care       Date:  2019 Jan-Feb

10.  Antioxidant and Anti-inflammatory Diagnostic Biomarkers in Multiple Sclerosis: A Machine Learning Study.

Authors:  Leda Mezzaroba; Andrea Name Colado Simão; Sayonara Rangel Oliveira; Tamires Flauzino; Daniela Frizon Alfieri; Wildea Lice de Carvalho Jennings Pereira; Ana Paula Kallaur; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Mol Neurobiol       Date:  2020-01-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.